Compare SQM & EXAS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SQM | EXAS |
|---|---|---|
| Founded | 1968 | 1995 |
| Country | Chile | United States |
| Employees | N/A | N/A |
| Industry | Mining & Quarrying of Nonmetallic Minerals (No Fuels) | Medical Specialities |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 17.6B | 11.0B |
| IPO Year | 1993 | N/A |
| Metric | SQM | EXAS |
|---|---|---|
| Price | $61.39 | $101.08 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 8 | 20 |
| Target Price | $50.81 | ★ $76.38 |
| AVG Volume (30 Days) | 2.1M | ★ 10.3M |
| Earning Date | 11-18-2025 | 11-03-2025 |
| Dividend Yield | ★ 3.45% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 1.84 | N/A |
| Revenue | ★ $4,326,111,000.00 | $3,082,033,000.00 |
| Revenue This Year | N/A | $19.40 |
| Revenue Next Year | $22.11 | $13.51 |
| P/E Ratio | $33.36 | ★ N/A |
| Revenue Growth | N/A | ★ 14.47 |
| 52 Week Low | $29.36 | $38.81 |
| 52 Week High | $65.65 | $101.87 |
| Indicator | SQM | EXAS |
|---|---|---|
| Relative Strength Index (RSI) | 61.38 | 89.74 |
| Support Level | $59.97 | $100.98 |
| Resistance Level | $65.65 | $101.43 |
| Average True Range (ATR) | 2.39 | 2.25 |
| MACD | -0.26 | 0.53 |
| Stochastic Oscillator | 48.65 | 97.74 |
Sociedad Quimica y Minera de Chile is a Chilean commodities producer with significant operations in lithium (primarily used in batteries for electric vehicles and energy storage systems), specialty and standard potassium fertilizers, iodine (primarily used in X-ray contrast media), and solar salts. The company extracts these materials through its high-quality salt brine deposits and caliche ore. SQM also sells lithium concentrate from a joint venture hard rock lithium project in Australia and expanding its lithium refining assets in China.
Exact Sciences, headquartered in Madison, Wisconsin, provides cancer screening and diagnostic test products in the United States and internationally. Exact's Cologuard screening test is a noninvasive stool-based DNA test for colorectal cancer. The company also competes in the precision oncology market with Oncotype DX, a suite of tissue-based genomic tests for estimating recurrence risk and likelihood of benefit from chemotherapy for breast and colon cancer, and OncoExTra, a liquid-based comprehensive genomic profiling test. It also has a pipeline of blood-based tests for molecular residual disease, colorectal cancer screening, and multicancer screening.